Reaction
Renal Cancer Recurrent reporting signals
As of the last recalculation, Renal Cancer Recurrent appears in 146 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is PAZOPANIB HYDROCHLORIDE (PRR 81.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pazopanib Hydrochloride | 14 | 81.5 | 81.5 |
| Axitinib | 7 | 53.8 | 53.8 |
| Cabozantinib | 12 | 38.7 | 38.7 |